Placebo News and Research

RSS

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Daily iron supplementation during pregnancy does not increase malaria risk in malaria-endemic region

Among women in a malaria-endemic region in Kenya, daily iron supplementation during pregnancy did not result in an increased risk of malaria, according to a study in the September 8 issue of JAMA. Iron supplementation did result in increased birth weight, gestational duration, neonatal length, and a decreased risk of low birth weight and prematurity.

9 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proof-of-concept ("POC") trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer ("NSCLC") in China.

4 Sep 2015

Acupuncture may be viable treatment for women experiencing hot flashes

Acupuncture may be a viable treatment for women experiencing hot flashes as a result of estrogen-targeting therapies to treat breast cancer, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania. Hot flashes are particularly severe and frequent in breast cancer survivors, but current FDA-approved remedies for these unpleasant episodes, such as hormone replacement therapies are off-limits to breast cancer survivors because they include estrogen.

4 Sep 2015

Acupuncture: A viable treatment for breast cancer survivors experiencing hot flashes

3 Sep 2015

Scientists pinpoint neurons responsible for alcohol consumption

Scientists have pinpointed a population of neurons in the brain that influences whether one drink leads to two, which could ultimately lead to a cure for alcoholism and other addictions.

3 Sep 2015

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

3 Sep 2015

Mouse study shows active ingredient in marijuana may delay rejection of incompatible organs

Here's another discovery to bolster the case for medical marijuana: New research in mice suggests that THC, the active ingredient in marijuana, may delay the rejection of incompatible organs.

2 Sep 2015

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA.

2 Sep 2015

Familial hypercholesterolemia patients can benefit from alirocumab drug

Alirocumab lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to results from four ODYSSEY trials presented at ESC Congress today.

2 Sep 2015

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease.

2 Sep 2015

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to findings from the ATLANTIC-H24 study presented for the first time today at ESC Congress.

1 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year.

1 Sep 2015

$Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction$

Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction

Gene transfer therapy aimed at correcting an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in heart failure patients with reduced ejection fraction, results of the CUPID 2 study show.

1 Sep 2015

BCM injection does not prevent cardiac remodeling in heart attack patients

An investigational material known Bioabsorbable Cardiac Matrix (BCM) that is injected through the coronary artery to prevent cardiac remodelling in heart attack patients had no significant effect compared to a saline placebo, according to results of the PRESERVATION I trial.

1 Sep 2015

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show.

1 Sep 2015

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

HIV-1 infection with multiple founder variants points to poorer clinical outcomes than infection with a single variant, according to a paper published today in the journal Nature Medicine.

1 Sep 2015

Placebo News and Research

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Daily iron supplementation during pregnancy does not increase malaria risk in malaria-endemic region

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

AstraZeneca presents lung cancer research data at WCLC 2015

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Acupuncture may be viable treatment for women experiencing hot flashes

Acupuncture: A viable treatment for breast cancer survivors experiencing hot flashes

Scientists pinpoint neurons responsible for alcohol consumption

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Mouse study shows active ingredient in marijuana may delay rejection of incompatible organs

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Familial hypercholesterolemia patients can benefit from alirocumab drug

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction

BCM injection does not prevent cardiac remodeling in heart attack patients

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News